SORA:NASDAQAsiaStrategy Analysis
Data as of 2026-05-26 - not real-time
$2.65
Latest Price
8/10Risk
Risk Level: High
Executive Summary
AsiaStrategy (SORA) is trading just below its 20‑day SMA of $2.67 and above its 50‑day SMA, while the RSI sits at a neutral 54.5 and the MACD histogram is negative, signalling short‑term bearish momentum. Volatility is extreme at 84% over the past 30 days and a computed beta of 2.68 underscores its sensitivity to market swings. The company’s fundamentals are weak: revenue fell 32% year‑over‑year, gross margin is a meager 3.5%, operating margin is negative and cash flow remains deeply negative, yet it still carries $14.2 M of debt against $19.3 M of cash, resulting in a high price‑to‑book of 7.4. Recent commentary suggests earnings may be weaker than anticipated, adding to the downside pressure.
Given the combination of a fragile earnings outlook, high leverage, and a market environment of “Extreme Greed,” the stock appears overvalued relative to its deteriorating fundamentals. Liquidity is thin, with daily volume well below its 10‑day average, and the price is hovering near a support level around $2.01, making the near‑term risk profile especially elevated.
Given the combination of a fragile earnings outlook, high leverage, and a market environment of “Extreme Greed,” the stock appears overvalued relative to its deteriorating fundamentals. Liquidity is thin, with daily volume well below its 10‑day average, and the price is hovering near a support level around $2.01, making the near‑term risk profile especially elevated.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Bearish MACD and decreasing volume
- Proximity to technical support level
- Weak earnings outlook highlighted in recent news
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Continued revenue decline and negative cash flow
- High debt load despite net cash cushion
- Elevated volatility and beta
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Fundamental turnaround required to justify price
- Sector exposure to discretionary spending cycles
- Liquidity constraints and thin market depth
Key Metrics & Analysis
Financial Health
Revenue Growth-31.90%
Profit Margin111.91%
P/E Ratio5.3
ROE106.10%
ROA-4.25%
Debt/Equity64.95
P/B Ratio7.4
Op. Cash Flow$-4322067
Free Cash Flow$-7094222
Technical Analysis
TrendNeutral
RSI54.5
Support$2.01
Resistance$2.87
MA 20$2.67
MA 50$2.31
MA 200$3.52
MACDBearish
VolumeDecreasing
Fear & Greed Index91.25
Valuation
GradeOvervalued
TypeValue
Risk Assessment
Beta2.68
Volatility84.10%
Sector RiskHigh
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.